Page 2 - Year Report News Today

MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent

Quarterly Activity Report Q3 FY24 Highlights • Completion of enrolment in first trial of sozinibercepts Phase 3 pivotal program...

Xlife Sciences AG Key word Annual Results Xlife Sciences AG Publishes 2023 Annual Report 23Apr2024 0700 CETCEST Release of an ad hoc announcement pursuant to Art 53 LR The issuer is solely responsibl

Xlife Sciences AG / Key word: Annual Results Xlife Sciences AG Publishes 2023 Annual Report 23-Apr-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The...

Brings extensive experience in retinal and ophthalmology diseases...

Pakistan’s startup landscape largely led by tech startups in terms of both funding and growth has made significant...

Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee ChairMELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), toda...

Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair...

Investor Relations Newsletter2023 Financial Year Positives and negatives to take from financial year 2023 ...

HOUSTON, March 25, 2024 -- Today, Technip Energies and LanzaTech Global, Inc. were selected by the U.S. Department of Energy Office of Clean Energy Demonstrations to begin award negotiations for...